Spotlight On... GSK Australia plant to begin using blow-fill-seal technology for vaccines; Capsugel completes deal announced in Dec.; Allergan buys Anterios; CRO BioDuro names new CFO; and more...

GlaxoSmithKline ($GSK) has opened a new wing at its Boronia, Australia facility as part of an effort to develop a manufacturing technique that could make the operation the first to produce a vaccine delivered by using blow-fill-seal technology. The technology forms a container, fills and then seals it to maintain a high assurance of sterility. Initially, the vaccines produced at the plant will be targeted for emerging countries. Vaccine experts from Belgium worked with the GSK team at the plant to develop the technique. GSK has invested $70 million (AU$100 million) in the unit with the Australian government pitching in a $700,000 (AU$1 million) grant. Article

> Capsugel has completed its acquisitions of Xcelience and Powdersize, which the company announced last month. Announcement

> Allergan ($AGN) has acquired Anterios, which is developing a new delivery system and botulinum toxin-based prescription products, for $90 million and other considerations. Announcement

> BioDuro, a California-based CRO specializing in preclinical chemistry, biology and fully outsourced integrated drug development, has named Ian R. Wisenberg as its chief Financial Officer. Announcement

 

 

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.